Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00602
UPID:
FCN1_HUMAN
Alternative names:
Collagen/fibrinogen domain-containing protein 1; Ficolin-A; Ficolin-alpha; M-ficolin
Alternative UPACC:
O00602; Q5VYV5; Q92596
Background:
Ficolin-1, also known as Collagen/fibrinogen domain-containing protein 1, Ficolin-A, and Ficolin-alpha, plays a pivotal role in innate immunity. It functions as an extracellular lectin, recognizing and binding to sugar moieties of pathogen-associated molecular patterns (PAMPs) on microbes. This action activates the lectin pathway of the complement system and may also trigger monocyte activation via FFAR2, leading to interleukin-8 secretion.
Therapeutic significance:
Understanding the role of Ficolin-1 could open doors to potential therapeutic strategies.